PMA Submission Guide: FDA Requirements, Timelines, and Best Practices

Last Updated: November 2026

For medical device manufacturers, the Premarket Approval (PMA) process is the most rigorous path to market in the United States. Reserved for Class III devices that sustain life, prevent serious impairment, or present the greatest risk to patients, a PMA submission demands comprehensive clinical data, validated manufacturing processes, and a clear demonstration of both safety and effectiveness.

Unlike a 510(k), where manufacturers can show substantial equivalence to an existing device, a PMA is built from the ground up. Every detail must stand on its own merit, from nonclinical studies through pivotal clinical trials.

For sponsors, preparing a PMA is a pivotal milestone that determines how quickly their innovation reaches the market, how smoothly it survives an FDA audit, and ultimately, how soon it can start improving or even saving lives.

What does a PMA submission require? A PMA submission is the FDA's most rigorous review path, required for Class III devices. It must include administrative information, a device description, nonclinical and clinical studies, manufacturing and quality information, labeling, and an environmental assessment. FDA decides within 180 days of filing, but amendments and inspections often extend that, and FY2027 fees start at $636,732 ($159,183 for small businesses).

In this guide

• What is a PMA submission?
• Key components of a PMA application
• The PMA review process
• How long does PMA review take?
• PMA clinical trials: what evidence does FDA expect?
• Common challenges
• PMA vs. 510(k) vs. De Novo
• Quality system requirements: QMSR and inspections
• PMA costs: FY2027 FDA user fees
• How sponsors can streamline the PMA process
• How Kivo and other platforms compare for PMA documentation
• How Kivo supports PMA submissions
• PMA submission FAQ

What is a PMA Submission?

A Premarket Approval (PMA) is the FDA's highest standard of review for medical devices. Defined under 21 CFR Part 814, it applies to Class III devices that support or sustain human life, are essential in preventing serious health impairment, or pose a significant risk of illness or injury if they fail.

Unlike the 510(k) process, a PMA requires a sponsor to generate and present original evidence: clinical trial data, detailed descriptions of the device and its intended use, and full documentation of manufacturing processes. The FDA evaluates not just whether the device works, but whether it consistently performs as intended under real-world conditions.

Key Components of a PMA Application

The FDA expects a PMA submission to be comprehensive, structured, and supported by data that can withstand regulatory and scientific scrutiny. Each application must include:

• Administrative Information: Required FDA forms, sponsor details, and financial disclosure statements for investigators.

• Device Description and Indications for Use: A full technical overview of the device, its components, and the specific clinical purpose it is designed to serve.

• Nonclinical Laboratory Studies: Bench testing, biocompatibility, toxicology, and other preclinical data to show the device functions as intended under controlled conditions.

• Clinical Data: Results from pivotal trials and supporting studies that demonstrate the device is safe and effective for its intended use. This section is often the heart of the PMA.

• Manufacturing Information: Documentation of facilities, processes, and quality controls, showing devices can be produced consistently at scale under the Quality Management System Regulation (QMSR, 21 CFR Part 820).

• Proposed Labeling: Draft instructions for use, indications, contraindications, warnings, and marketing materials that must align with the evidence provided.

• Environmental Assessment: An evaluation of the environmental impact of manufacturing and distribution, or a claim of categorical exclusion.

Each component must connect back to the central requirement: proving that the device is both safe and effective. Applicable trials also need a Form FDA-3674 ClinicalTrials.gov certification. Incomplete or inconsistent documentation often leads to FDA deficiency letters and costly delays.

There are three ways to assemble a PMA. A traditional PMA is submitted complete. A modular PMA is submitted in sections that FDA reviews as each is finished, which suits products still in early clinical study. A Product Development Protocol (PDP) combines clinical evaluation and approval data development under an agreement with FDA and fits well-established technologies. (Source: FDA, PMA Application Methods.)

The PMA Review Process

Once a PMA is submitted, the FDA follows a structured review pathway designed to evaluate safety, effectiveness, and manufacturing quality. The process typically includes:

1. Filing Review

Within 45 days, the FDA determines whether the submission is administratively complete. If key elements are missing, the application may be refused for filing.

2. Substantive Review

FDA scientific and regulatory experts evaluate the nonclinical, clinical, and manufacturing data in depth. This stage often involves multiple requests for additional information.

3. Advisory Panel Review

For certain high-profile or novel devices, an external advisory committee of clinical and scientific experts is convened to provide recommendations. While advisory input is not binding, it heavily informs the FDA's decision.

4. Inspection

The FDA may conduct pre-approval inspections of manufacturing facilities to confirm compliance with the QMSR (21 CFR Part 820). Issues found at this stage can delay or prevent approval.

5. Final Decision

The FDA issues an Approval Order if all requirements are met. In other cases, the agency may send an "Approvable Letter" (pending additional conditions) or a "Not Approvable Letter."

How Long Does PMA Review Take? The 180-Day Clock and Real Timelines

FDA has 180 days from the filing date to decide a PMA, but amendments and your own response time stretch the real timeline well past that.

FDA tells you within 45 days of receipt whether the PMA is filed, then has 180 days to issue an approval order, approvable letter, not-approvable letter, or denial. A PMA amendment with significant new data can extend that clock by up to 180 days. A Day-100 meeting can be requested no later than 70 days after filing, and an approvable or not-approvable letter must be answered within 180 days or the application can be withdrawn. (Source: FDA, PMA Review Process.)

FDA's draft MDUFA VI commitment letter, posted in July 2026, proposes an average of 285 calendar days to a PMA decision. It is still a draft that must be enacted by September 30, 2027, so treat it as direction, not a commitment. (Source: MD+DI, July 2026.)

PMA Clinical Trials: What Evidence Does FDA Expect?

FDA decides a PMA on "valid scientific evidence" (21 CFR 860.7), and evidence of effectiveness must consist principally of well-controlled investigations. Isolated case reports and unsubstantiated opinion do not count.

A well-controlled device study states its objectives, assigns subjects to groups in a way that minimizes bias, uses a defined comparator (no treatment, placebo or sham, active control, or in limited cases a historical control), and pre-specifies statistical analysis and success criteria. U.S. studies must follow the IDE rule (21 CFR 812), informed consent (21 CFR 50), and IRB review (21 CFR 56).

The clinical section of the PMA should account for every subject, including dropouts, and report adverse events, protocol deviations, and missing data. Studies that rely on data from outside the U.S. should be discussed in a Pre-Submission meeting. (Source: FDA, PMA Clinical Studies, last updated February 2023.)

Common Challenges in PMA Submissions

PMA submissions carry the highest regulatory burden for medical devices. The most frequent obstacles include:

• Clinical Evidence Requirements: Designing pivotal studies that demonstrate both safety and effectiveness while meeting FDA expectations is one of the biggest hurdles.

• Manufacturing Readiness: Approval can stall if facilities are not fully validated; pre-approval inspections regularly uncover gaps in documentation, training, or quality controls.

• Data Volume and Complexity: Inconsistent formatting, version conflicts, or missing documentation across nonclinical, clinical, and manufacturing data often lead to deficiency letters.

• Labeling Alignment: Sponsors that overstate indications or fail to describe contraindications risk extended negotiations or outright rejection.

• Responding to FDA Deficiency Letters: Requests for additional information can add months of delay, so teams must locate, reconcile, and submit complete responses quickly. See our executive guide to medical device compliance for the wider picture.

PMA vs. 510(k) vs. De Novo

Medical device manufacturers often weigh different regulatory pathways. The distinctions are critical, and EU requirements add another layer (see EU MDR vs. FDA regulations).

Sources: FDA 510(k), FDA De Novo, and the Federal Register FY2027 fee notice. A successful De Novo device can later serve as a predicate for 510(k) submissions.

PMA Quality System Requirements: QMSR and Pre-Approval Inspections

Since February 2, 2026, the quality requirements in 21 CFR Part 820 are the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. FDA also retired its Quality System Inspection Technique that day and now inspects under Compliance Program 7382.850. (Source: FDA QMSR FAQ.)

One law firm's reading of that program is that PMA pre-approval inspections follow a more comprehensive model covering at least 22 quality-system elements for non-sterile devices and 23 for sterile devices, with CAPA a required element. (Source: King & Spalding, February 2026.) Build inspection readiness in parallel with clinical work; see our guide to ISO 13485.

PMA Costs: FY2027 FDA User Fees

FDA's FY2027 user fee for an original PMA is $636,732, or $159,183 for a qualifying small business (gross receipts of $100 million or less, including affiliates). The rates apply to payments received from October 1, 2026 through September 30, 2027, and small-business status must be requested at least 60 days before the fee is due. (Source: Federal Register.)

Fees are only part of the investment. Pivotal clinical trials are typically the largest cost, and manufacturing readiness adds another layer, since facilities must comply with the QMSR before approval. Delays mean lost revenue and extended burn, so companies that anticipate FDA requests are better positioned to keep programs moving.

How Sponsors Can Streamline the PMA Process

Although a PMA submission is inherently complex, sponsors can reduce risk and avoid unnecessary delays by preparing across four areas:

• Early FDA Engagement: Pre-Submission (Pre-Sub) meetings allow sponsors to align on study design, data requirements, and submission structure before investing heavily in trials.

• Robust Clinical Trial Planning: Trials must be powered not just to show effectiveness, but also to satisfy FDA expectations on safety endpoints and patient diversity.

• Manufacturing and Quality Readiness: Treat inspection readiness as parallel to clinical trial execution, not a downstream task.

• Strong Document Management: A unified system for regulatory, clinical, and quality documentation eliminates version conflicts and accelerates responses to deficiency letters.

How Kivo and Other Regulatory Platforms Compare for PMA Documentation

A PMA is a document-heavy filing, so many sponsors look at a regulatory information management (RIM) or document system to keep it organized. This is not an independent ranking. It does not assess implementation quality, market share, or fit for any particular organization; validate every option against your own requirements.

How Kivo Supports PMA Submissions

Kivo centralizes regulatory, clinical, and quality documentation in a single validated platform, so sponsors can respond to FDA information requests faster and keep cross-functional teams on the same version of every file. Kivo also offers one of the few Quality Management Systems designed with medical device teams in mind, and users are experiencing expedited development timelines as a result.

For PMA work, teams use Kivo to assemble Pre-Submission briefing packages from controlled documents, keep trial protocols and amendments in one structured system, hold quality and regulatory documents together for inspection prep, and configure workflows to their own SOPs.

Next Steps

For Class III medical devices, the Premarket Approval pathway is the highest bar to market entry. Sponsors who prepare early, engage proactively with the FDA, and keep documentation unified are best positioned to navigate PMA review, including the post-market obligations that follow approval. Click below to demo the platform and speak with our experienced team of life sciences professionals.

PMA Submission FAQ

How long does FDA take to review a PMA?

FDA tells you within 45 days whether a PMA is filed, then has 180 days from the filing date to decide. Amendments with significant new data can extend that by up to 180 days, and time spent answering FDA questions is additional, so real-world timelines run longer.

How much does a PMA cost in 2027?

The FY2027 FDA user fee for an original PMA is $636,732, or $159,183 for a qualifying small business, for payments received October 1, 2026 through September 30, 2027. Clinical trials, manufacturing readiness, and consulting are separate costs.

Do you need clinical trials for a PMA?

A PMA must show safety and effectiveness with valid scientific evidence, and effectiveness evidence must consist principally of well-controlled investigations. For most Class III devices that means a clinical study run under an IDE, though FDA accepts other valid evidence depending on the device.

What is the difference between a PMA and a 510(k)?

A 510(k) shows a device is substantially equivalent to a predicate and is typically used for Class II devices. A PMA is required for Class III devices and needs original evidence of safety and effectiveness plus manufacturing and quality information, reviewed against a higher standard.

What is a modular PMA?

A modular PMA is submitted in sections, such as nonclinical, clinical, and manufacturing modules, that FDA reviews as each is completed under an agreed outline. It is recommended for products still in early clinical study; a traditional PMA is submitted complete.